Topic: inter partes review
Biogen investors have been on a wild ride in recent months, and on Wednesday they experienced their first major jolt in 2020.
Amgen persuaded the U.S. patent office to weigh three Alexion patents protecting Soliris, previously considered safe from copycats till 2027.
The government's patents on Gilead's Truvada have made plenty of headlines lately, and that's a distraction, Gilead figures.
Much of the doubt surrounding BMS' $74 billion Celgene buy centers on Revlimid's patent life. But the companies just scored a win in that department.
Biogen has been working hard to build out its pipeline, but as that effort plays out, the biotech faces a new patent challenge to its top moneymaker.
An appeals court rejected Allergan's attempt to protect Restasis patents with sovereign immunity, clearing the way for generics.
After a federal appeals court put Allergan's tribal licensing deal under review, judges scrutinized the arguments this week.
Dealing a blow to branded drugmakers, the U.S. Supreme Court found that inter partes review patent challenges are constitutional.
Allergan took all kinds of criticism for its tribal licensing deal, but an appeals court decision has breathed new life into the strategy.
After a Friday ruling, Allergan's eye drug Restasis has to face the very patent challenge the company sought to prevent.